← Leaderboards
Padmanee Sharma
University Of Tx Md Anderson Can Ctr
$2,235,712
Attributed
$3,487,648
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $636.6K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,487,648 · 2
By mechanism
R01$3,487,648 · 2
Top collaborators
- Ana Aparicio3 shared
- Daniel Edward Frigo3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Di Zhao$3,648,377
- John V. Heymach$11,138,593
- Gregory K Friedman$1,249,774
- Chandra Bartholomeusz$954,403
- Min Gyu Lee$8,063,863
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneMediatingCellsCombined Modality TherapySignal TransductionPathway InteractionsMouse ModelResponseTumorClinical DataEffective TherapyCell PhysiologyClinical TrialsReportingPre-ClinicalCytoplasmic TailAntigen-Presenting CellsDesignApplications GrantsAffectCytokineCancer ImmunotherapyB-LymphocytesCd8b1 Gene
Grant awards (8)
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)$636,578
R01 · FY2025 · CA
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)$604,748
R01 · FY2024 · CA
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)$636,578
R01 · FY2023 · CA
Targeting the ICOS/ICOSL pathway to improve anti-tumor immune responses$327,850
R01 · FY2016 · CA · contact PI
Targeting the ICOS/ICOSL pathway to improve anti-tumor immune responses$327,850
R01 · FY2015 · CA · contact PI
Targeting the ICOS/ICOSL pathway to improve anti-tumor immune responses$318,015
R01 · FY2014 · CA · contact PI
Targeting the ICOS/ICOSL pathway to improve anti-tumor immune responses$308,179
R01 · FY2013 · CA · contact PI
Targeting the ICOS/ICOSL pathway to improve anti-tumor immune responses$327,850
R01 · FY2012 · CA · contact PI